openPR Logo
Press release

Tosymra - Drug Insight and Forecast, 2018

04-24-2019 08:54 AM CET | Health & Medicine

Press release from: Tosymra - Pharma Proff

Tosymra, previously known as DFN-02, an intranasal spray containing sumatriptan (10 mg) and a 5-HT1B/1D receptor agonist developed by Dr. Reddy’s Laboratories Limited and its subsidiary Promius Pharma, LLC, is approved by the USFDA in January, 2019 for the acute migraine.

Download the sample report at: https://www.pharmaproff.com/request-sample/1169

In a multicenter, double blinded, randomized, placebo-controlled study, Tosymra was found to be safe, effective and well tolerated. As compared to the other sumatriptan products, Tosymra is contradicted in patients with a history of coronary artery disease or coronary artery vasospasm, Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders, history of stroke, transient ischemic attack, or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke, peripheral vascular disease, ischemic bowel disease, uncontrolled hypertension, or severe hepatic impairment.

Get the detailed analysis at: https://www.pharmaproff.com/report/tosymra

The spray contains a permeation-enhancing excipient (Intravail), which allows the product to be quickly absorbed into the systemic circulation while demonstrating a similar pharmacokinetic profile as subcutaneous sumatriptan.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1169

The report provides a comprehensive understanding of the drug, covering all the API manufactures and its details in the 7 major markets which includes EU5 (U.K., Spain, Germany, Italy and France), U.S., and Japan. It covers all patents and strategic developments reported in this drug area. It highlights the historical and forecasted sales along with the market scenario, market competition and the historical and emerging therapies. The report is inclusive of SWOT and PESTLE analysis, depending on the information availability.

Moreover, the report also provides a comprehensive understanding of the pipeline activities of the drug candidate under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drug by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tosymra - Drug Insight and Forecast, 2018 here

News-ID: 1715215 • Views: …

More Releases for Reddy’s

Clopidogrel Market 2025 | Pfizer, Dr Reddy’s, Apotex Corp, Roxane Laboratories …
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are…
Dr. Vishnu Reddy’s Clinic announces HealthCare360 to deliver a comprehensive p …
Healthcare experience has seen a surge as teleconsultations follow the long-pending telemedicine guidelines which were recently issued by the ministry of health. This launch will exponentially increase the score of telemedicine space, both patients and doctors have relied on the sector. Hyderabad, India (07 July 2020) - Dr. Vishnu Reddy’s Clinic, a Hyderabad based renowned ENT & Facial Plastic clinic today announced the launch of, brand new healthcare experience for their…
Clopidogrel Market Global Forecasts upto 2017-2025 | Pfizer, Dr Reddy’s, Apote …
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are…
Clopidogrel Market Key Contributors 2017-2025 : Pfizer, Dr Reddy’s, Apotex Cor …
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are…
Clopidogrel Market - Top leading manufacturers 2025 | Pfizer, Dr Reddy’s
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are…
Survey: Atorvastatin Market Size 2018-2025 Pfizer, Morepen, Topfond, Dr. Reddy†…
Atorvastatin Market Research 2018 A market study "Global Atorvastatin Market" examines the performance of the Atorvastatin market 2018. It encloses an in-depth Research of the Atorvastatin market state and the competitive landscape Globally. This report analyzes the potential of Atorvastatin market in the present and the future prospects from various angles in detail. The Global Atorvastatin Market 2018 report includes Atorvastatin market Revenue, market Share, Atorvastatin industry volume, market Trends, Atorvastatin Growth…